Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.

Rui HuangHonghua HeXiaoli XuXiaonan LinYing DongXiaotao WangFang JiangPengcheng HuangShuyi MoZhenqian HuangYaya WangHongfang TaoYaling ZhengMing WuChuting YangZiyu ZhengYing ZhaoYuming ZhangYuhua Li

Published in: Cancer (2024)

The VEN/HMA regimen may result in a better response than CAG-based treatment in older patients with newly diagnosed AML.

Keyphrases

newly diagnosed
acute myeloid leukemia
allogeneic hematopoietic stem cell transplantation
physical activity
high dose
locally advanced
community dwelling
combination therapy
radiation therapy
acute lymphoblastic leukemia